Encoded Therapeutics
PrivateLast Round
Series F
Sep 9, 2026
Total Funding Raised
$239.1M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Encoded Therapeutics is a biotechnology company developing precision genetic medicines for severe neurological disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Encoded Therapeutics Comparables
Compare Encoded Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Stoke Therapeutics, Inc. | 84% | |
| Neurogene | 79% | |
| Regel Therapeutics | 79% |
Encoded Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series F | Sep 9, 2026 | ||||
| Series D | Jul 22, 2020 | ||||
| Series C | Jun 26, 2019 | ||||
| Seed | Apr 18, 2017 | ||||
| Accelerator | Jul 30, 2015 | ||||
Accelerator | Oct 15, 2014 |
Key People
Founding team and executive leadership
Encoded Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series F |
| SoftBank Investment Advisers | Series D, Series F |
| Farallon Capital Management | Series D, Series F |
| Boxer Capital | Series C, Series D |
| GV | Series D, Series F |
| Altitude Life Science Ventures | Series C, Seed |
| Braidwell | Series F |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 9, 2026
$275M round led by GV.
- Jun 7, 2026
ETX101 is the flagship clinical program for Dravet syndrome.
Recent news
Latest coverage and updates
- receives_financingSep 9, 2026
Encoded Therapeutics, Inc. closed a $275M Series F financing co-led by GV and another healthcare fund, with participation from new and existing investors, to advance ETX101 through pivotal development, expand its neurology pipeline, and scale internal GMP manufacturing in California.
- attends_eventSep 8, 2026
Encoded Therapeutics, Inc. attended event 16th European Epilepsy Congress on Sep 7th '26.
Encoded Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Encoded Therapeutics's valuation, stock price, and market status.
Is Encoded Therapeutics a public or private company?
Encoded Therapeutics is a private company.
What is the current stock price of Encoded Therapeutics?
Encoded Therapeutics is a private company, so its shares have no public market price. Caplight tracks Encoded Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Encoded Therapeutics worth (valuation)?
Valuation information for Encoded Therapeutics is not publicly available.
Can I buy Encoded Therapeutics stock?
Encoded Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Encoded Therapeutics's last funding round?
Encoded Therapeutics's most recent funding round was Series F on September 9, 2026.
Who are the main investors in Encoded Therapeutics?
Key investors in Encoded Therapeutics include GV, Menlo Ventures, Illumina Accelerator.
Will Encoded Therapeutics IPO soon?
No public IPO plans have been announced for Encoded Therapeutics.
How can I track Encoded Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Encoded Therapeutics's shares on secondary markets.